STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

Game-Changing Alliance: Adia Labs and Axia

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Very Positive)
Tags

Adia Nutrition (OTCQB: ADIA) announced a strategic partnership between its research arm Adia Labs and AxiaMD on November 10, 2025.

Under the agreement, AxiaMD's nationwide physician-oversight network will offer Adia Labs' regenerative products to clients while Adia's clinics gain AxiaMD's compliance and oversight services across all 50 states, enabling chiropractic clinics to perform advanced regenerative procedures under full physician oversight. The release highlights FDA-compliant stem cell products, a mutual referral model, and prior company momentum including 200%+ Q3 2025 revenue growth and an OTCQB uplisting toward Nasdaq eligibility.

Adia Nutrition (OTCQB: ADIA) ha annunciato una partnership strategica tra il suo braccio di ricerca Adia Labs e AxiaMD il 10 novembre 2025. Sotto l'accordo, la rete nazionale di supervisione medica di AxiaMD offrirà i prodotti rigenerativi di Adia Labs ai clienti, mentre le cliniche di Adia avranno i servizi di conformità e supervisione di AxiaMD in tutti i 50 stati, consentendo alle cliniche chiropratiche di eseguire procedure rigenerative avanzate sotto la supervisione completa di un medico. Il comunicato evidenzia prodotti a base di cellule staminali conformi alla FDA, un modello di riferimento reciproco e la spinta precedente della società includendo crescita dei ricavi nel terzo trimestre 2025 superiore al 200% e un uplisting OTCQB verso l'idoneità Nasdaq.
Adia Nutrition (OTCQB: ADIA) anunció una asociación estratégica entre su brazo de investigación Adia Labs y AxiaMD el 10 de noviembre de 2025. Bajo el acuerdo, la red nacional de supervisión médica de AxiaMD ofrecerá los productos regenerativos de Adia Labs a los clientes, mientras que las clínicas de Adia obtendrán los servicios de cumplimiento y supervisión de AxiaMD en los 50 estados, permitiendo a las clínicas quiroprácticas realizar procedimientos regenerativos avanzados bajo la supervisión total de un médico. El comunicado destaca productos de células madre compatibles con la FDA, un modelo de referencia mutua y la impulsión previa de la empresa, incluyendo un crecimiento de ingresos del 3T 2025 superior al 200% y un uplisting de OTCQB hacia la elegibilidad de Nasdaq.
Adia Nutrition(OTCQB: ADIA)가 2025년 11월 10일 연구 부문 Adia LabsAxiaMD 간의 전략적 파트너십을 발표했습니다. 합의에 따라 AxiaMD의 전국적 의사 감독 네트워크가 Adia Labs의 재생 의약품을 고객에게 제공하는 한편, Adia의 클리닉은 모든 50개 주에서 AxiaMD의 준수 및 감독 서비스를 확보하여 척추지압 클리닉이 의사의 전면 감독 아래 고급 재생 시술을 수행할 수 있게 됩니다. 발표는 FDA 규정 준수 줄기세포 제품를 강조하고, 상호 추천 모델과 회사의 이전 모멘텀으로 2025년 3분기 매출이 200% 이상 성장OTCQB Nasdaq 적합성 향한 업라이팅을 포함합니다.
Adia Nutrition (OTCQB: ADIA) a annoncé le 10 novembre 2025 un partenariat stratégique entre son bras de recherche Adia Labs et AxiaMD. Dans le cadre de l’accord, le réseau national de supervision médicale d'AxiaMD offrira les produits régénératifs d'Adia Labs à ses clients, tandis que les cliniques d'Adia bénéficieront des services de conformité et de supervision d'AxiaMD dans les 50 États, permettant aux cliniques chiropratiques d'effectuer des procédures régénératives avancées sous la supervision complète d’un médecin. Le communiqué met en avant des produits à base de cellules souches conformes à la FDA, un modèle de référence mutuelle et l’élan antérieur de l’entreprise comprenant une croissance des revenus du T3 2025 >200% et une montée en bourse OTCQB vers l’éligibilité Nasdaq.
Adia Nutrition (OTCQB: ADIA) kündigte am 10. November 2025 eine strategische Partnerschaft zwischen ihrem Forschungsarm Adia Labs und AxiaMD an. Im Rahmen der Vereinbarung wird AxiaMDs landesweites Netzwerk zur ärztlichen Aufsicht Adia Labs' regenerative Produkte den Kunden anbieten, während Adias Kliniken AxiaMDs Compliance- und Aufsichtsservices in allen 50 Bundesstaaten erhalten und chiropraktische Kliniken fortgeschrittene regenerative Verfahren unter vollständiger ärztlicher Aufsicht durchführen können. Die Mitteilung hebt FDA-konforme Stammzellprodukte, ein gegenseitig empfohlenes Modell und die bisherige Dynamik des Unternehmens hervor, einschließlich einem Umsatzwachstum im Q3 2025 von über 200% und einem OTCQB-Uplisting in Richtung Nasdaq-Berechtigung.
أعلنت Adia Nutrition (OTCQB: ADIA) عن شراكة استراتيجية بين ذراعها البحثي Adia Labs و AxiaMD في 10 نوفمبر 2025. وفقًا للاتفاق، ستوفر شبكة إشراف الأطباء على مستوى البلاد لدى AxiaMD منتجات Adia Labs التجديدية للعملاء، بينما ستكتسب عيادات Adia خدمات الامتثال والإشراف من AxiaMD في جميع الولايات الخمسين، مما يمكن عيادات العلاج بتقويم العمود الفقري من إجراء إجراءات تجديد متقدمة تحت إشراف طبي كامل. يبرز البيان منتجات الخلايا الجذعية المتوافقة مع FDA ونموذج الإحالة المتبادل والدافع السابق للشركة بما في ذلك نمو في الإيرادات في الربع الثالث 2025 يتجاوز 200% وارتفاع OTCQB نحو أهلية Nasdaq.
Positive
  • 200%+ Q3 2025 revenue growth reported
  • Partnership enables nationwide rollout under physician oversight
  • FDA-compliant stem cell products available to AxiaMD network
  • Access to AxiaMD compliance supports scalable multi-state operations
  • OTCQB uplisting progress toward Nasdaq eligibility
Negative
  • None.

MD Bring Regenerative therapies to Chiropractors Nationwide with Full Physician Oversight

Winter Park, Florida--(Newsfile Corp. - November 10, 2025) - Adia Nutrition Inc. (OTCQB: ADIA), a leader in regenerative medicine and premium wellness solutions, today announced a strategic partnership between its research and development division, Adia Labs, and AxiaMD, a premier provider of nationwide physician oversight and compliance services for med spas, IV clinics, physician assistants, nurse practitioners, and wellness practices.

Under the agreement, AxiaMD's extensive network of healthcare providers will offer Adia Labs' flagship regenerative products to their clients. In turn, Adia Nutrition's growing ecosystem of clinics and partners will gain access to AxiaMD's expert compliance and physician oversight services to ensure seamless, fully compliant operations across all 50 states. This partnership now allows chiropractic clinics to perform these advanced regenerative procedures under full physician oversight and regulatory compliance.

This mutual referral model creates a powerful synergy:

  • Adia Labs' FDA-compliant stem cell products are now available to AxiaMD's nationwide client base.
  • Adia Med clients and partners benefit from AxiaMD's turnkey regulatory support, enabling faster scaling with confidence.

"AxiaMD's unmatched compliance infrastructure is the perfect complement to Adia Labs' cutting-edge regenerative products," said Larry Powalisz, CEO of Adia Nutrition Inc. "By integrating Adia's regenerative products into their network while leveraging AxiaMD's oversight for client operations, we're building a compliant, scalable national platform that accelerates access to transformative therapies."

AxiaMD specializes in physician-led oversight, custom protocols, and proactive compliance, allowing wellness and medical practices to operate with full regulatory confidence.

"This partnership with Adia Labs empowers our providers with access to best-in-class regenerative products while strengthening compliance across the board," said a spokesperson for AxiaMD. "We're proud to support Adia's mission and excited to bring AdiaVita and AdiaLink to our clients nationwide."

This collaboration builds on Adia Nutrition's 2025 momentum, including 200%+ Q3 revenue growth and OTCQB uplisting toward Nasdaq eligibility.

For questions, inquiries, or additional information, please contact Larry Powalisz at ceo@adiamed.com or by phone at 321-788-0850. Clinic owners and healthcare practitioners interested in licensing the Adia Med name or integrating Adia's regenerative therapies into their practice are encouraged to reach out directly. Strategic partnerships are welcomed as part of Adia's continued mission to expand access to advanced stem cell solutions.

About ADIA Nutrition Inc.:
Adia Nutrition Inc. (OTCQB: ADIA), based in Winter Park, Florida, is a publicly traded company advancing healthcare through innovation. The company specializes in sales of stem cell and regenerative products, such as AdiaVita and AdiaLink, through its lab division, AdiaLabs LLC, which is expanding to include insurance-billable wound care products. Adia is also growing nationwide with Adia Med clinics, specializing in orthopedic, pain management, and wound repair. Adia Med clinics also offer specialized regenerative treatments like stem cell therapies and platelet-rich plasma (PRP), advanced treatments including therapeutic plasma exchange (TPE) and autologous hematopoietic stem cell transplantation (aHSCT), and wound repair services.

Revenue is generated through service fees, product sales, equity stakes, and billing insurance for healthcare treatments. Additionally, Adia Nutrition Inc. invests in aligned businesses such as Cement Factory LLC, a nutrition and supplement company with shared values and a focus on health and wellness. Through bold partnerships with top-tier medical entities and unwavering dedication to standardized, FDA-approved lab protocols, Adia Nutrition Inc. is revolutionizing healthcare, igniting a nationwide movement to empower communities with groundbreaking regenerative solutions and vibrant, holistic wellness.

Website: www.adianutrition.com
Website: www.adiamed.com
Website: www.adialabs.com
Website: www.cementfactory.co
Twitter (X): @ADIA_Nutrition

Safe Harbor: This Press Release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based on the current plans and expectations of management and are subject to a few uncertainties and risks that could significantly affect the company's current plans and expectations, as well as future results of operations and financial condition. A more extensive listing of risks and factors that may affect the company's business prospects and cause actual results to differ materially from those described in the forward-looking statements can be found in the reports and other documents filed by the company with the Securities and Exchange Commission and OTC Markets, Inc. OTC Disclosure and News Service. The company undertakes no obligation to publicly update or revise any forward-looking statements, because of new information, future events or otherwise.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/273818

FAQ

What did Adia Nutrition (ADIA) announce on November 10, 2025?

Adia announced a strategic partnership between Adia Labs and AxiaMD to combine regenerative products with nationwide physician oversight.

How does the Adia Labs–AxiaMD deal affect chiropractic clinics using ADIA products?

The partnership allows chiropractic clinics to perform advanced regenerative procedures under full physician oversight and regulatory compliance across all 50 states.

What financial progress did Adia (ADIA) cite in the announcement?

The company cited 200%+ Q3 2025 revenue growth and an OTCQB uplisting toward Nasdaq eligibility.

Are Adia Labs' regenerative products described as FDA-compliant for ADIA?

Yes; the release describes Adia Labs' stem cell products as FDA-compliant.

How will AxiaMD support Adia Nutrition's expansion

AxiaMD provides nationwide physician-led oversight, custom protocols, and turnkey compliance to enable faster, compliant scaling.
Adia Nutrition

OTC:ADIA

ADIA Rankings

ADIA Latest News

ADIA Stock Data

4.51M
Shell Companies
Financial Services
Link
United States
Winter Park